Standout Papers

Improvements in survival and clinical benefit with gemcit... 1979 2026 1994 2010 4.6k
  1. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. (1997)
    Howard A. Burris, Malcolm J. Moore et al. Journal of Clinical Oncology
  2. Risk Factors for Doxorubicin-lnduced Congestive Heart Failure (1979)
    Daniel D. Von Hoff et al. Annals of Internal Medicine
  3. Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma (2012)
    Paolo P. Provenzano, Carlos Cuevas et al. Cancer Cell
  4. Hypersensitivity reactions from taxol. (1990)
    R B Weiss, Ross C. Donehower et al. Journal of Clinical Oncology
  5. Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma (2009)
    Daniel D. Von Hoff, Patricia LoRusso et al. New England Journal of Medicine
  6. Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies (2001)
    Manuel Hidalgo, Lillian L. Siu et al. Journal of Clinical Oncology
  7. Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial (2011)
    Daniel D. Von Hoff, Ramesh K. Ramanathan et al. Journal of Clinical Oncology
  8. Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449 (2009)
    Charles M. Rudin, Christine L. Hann et al. New England Journal of Medicine
  9. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents (1997)
    Carla Heise, Adam Sampson-Johannes et al. Nature Medicine
  10. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. (1990)
    Kevin E. Noonan, Christian Beck et al. Proceedings of the National Academy of Sciences
  11. nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial (2015)
    David Goldstein, Robert H. El-Maraghi et al. JNCI Journal of the National Cancer Institute
  12. Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer (2015)
    Clifford J. Whatcott, Caroline H. Diep et al. Clinical Cancer Research
  13. Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type (2014)
    Zoran Gatalica, Carrie Snyder et al. Cancer Epidemiology Biomarkers & Prevention
  14. Autophagy Is Critical for Pancreatic Tumor Growth and Progression in Tumors with p53 Alterations (2014)
    Annan Yang, N.V. Rajeshkumar et al. Cancer Discovery
  15. Triptolide and Its Derivatives as Cancer Therapies (2019)
    Pawan Noel, Daniel D. Von Hoff et al. Trends in Pharmacological Sciences

Immediate Impact

1 by Nobel laureates 21 from Science/Nature 102 standout
Sub-graph 1 of 20

Citing Papers

Pancreatic cancer: Advances and challenges
2023 Standout
Physical traits of cancer
2020 StandoutScience
65 intermediate papers

Works of Daniel D. Von Hoff being referenced

Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma
2012 Standout
Translational Therapeutic Opportunities in Ductal Adenocarcinoma of the Pancreas
2012
and 26 more

Author Peers

Author Last Decade Papers Cites
Daniel D. Von Hoff 23213 19391 8189 816 43.9k
Elisabeth G.E. de Vries 23721 14152 6262 1.0k 46.9k
Kenneth R. Hess 15103 9751 8322 506 40.9k
José Baselga 25287 19503 9567 482 45.7k
Scott M. Lippman 12512 13300 7757 520 36.3k
Masaki Mori 11859 21047 12288 1.3k 42.6k
Ka‐Fai To 8864 13389 7522 573 34.5k
Eleftherios P. Diamandis 9545 16868 6126 934 43.5k
Clifford A. Hudis 23054 8120 13808 509 38.8k
Jan H.M. Schellens 22295 15780 3692 878 40.3k
David L. Rimm 19402 17663 8058 541 40.3k

All Works

Loading papers...

Rankless by CCL
2026